UK & Europe

The United Kingdom and continental Europe.
Cell & Gene Therapy

Taranis Capital and EEC Partner to Build Next-Generation Data Centres

Taranis Capital and Emaar Executive Company partner to develop carrier-neutral data centres across Saudi Arabia, supporting rising AI and cloud demand under Vision 2030

Taranis Capital Limited (“Taranis”), a DFSA-regulated investment firm based in Dubai International Financial Centre (DIFC), has signed a Memorandum of Understanding (MOU) with Emaar Executive Company (EEC) to develop, construct, and operate a portfolio of next-generation, carr

Mark Walker  · 
Genomics

Inside the UK's £650m bet on genomic medicine

With Genomics England's newborn screening trial now enrolling, the Department of Health has made its most explicit commitment yet to whole-genome sequencing as frontline NHS infrastructure.

The UK government has quietly positioned itself at the front of a race few of its peers are even running.

Mark Walker  · 
Diagnostics
Pharmaceuticals

Royal Osteoporosis Society urges Britons to check bone health risk

New polling shows 80% of UK adults have never assessed their bone health, despite osteoporosis causing 550,000 fractures annually.
New polling shows 80% of UK adults have never assessed their bone health, despite osteoporosis causing 550,000 fractures annually.
The Biotech Times Editorial Team  · 
Medical Devices

Iridex MicroPulse TLT shows sustained IOP cuts in two-year study

An independent Italian study found MicroPulse transscleral laser therapy reduced intraocular pressure by 37% over 24 months across early to advanced glaucoma.
An independent Italian study found MicroPulse transscleral laser therapy reduced intraocular pressure by 37% over 24 months across early to advanced glaucoma.
The Biotech Times Editorial Team  · 
Cell & Gene Therapy
Biologics

Avaí Bio and Austrianova begin San Raffaele diabetes cell trial

The joint venture Insulinova has convened its first steering committee with OSR to evaluate encapsulated beta-cell replacement for insulin-dependent diabetes.
The joint venture Insulinova has convened its first steering committee with OSR to evaluate encapsulated beta-cell replacement for insulin-dependent diabetes.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Regulatory Science

Milestone Pharma enrols first European patient in AFib-RVR trial

Milestone Pharmaceuticals has expanded its ReVeRA-301 Phase 3 trial to Europe, enrolling the first patient through the Dutch WCN cardiovascular network.
Milestone Pharmaceuticals has expanded its ReVeRA-301 Phase 3 trial to Europe, enrolling the first patient through the Dutch WCN cardiovascular network.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Biologics

Idorsia aprocitentan shows double-digit BP cuts in obesity and CKM

Post hoc PRECISION analyses presented at AHA 2026 show aprocitentan cut systolic BP by over 15 mmHg and reduced UACR by nearly 50% in high
Post hoc PRECISION analyses presented at AHA 2026 show aprocitentan cut systolic BP by over 15 mmHg and reduced UACR by nearly 50% in high
The Biotech Times Editorial Team  · 
Biologics
Pharmaceuticals

NovaBridge to present givastomig Phase 1b data at ESMO 2026

Updated safety and efficacy data for the CLDN18.2x4-1BB bispecific will be presented at ESMO Congress in Madrid on 25 October.
Updated safety and efficacy data for the CLDN18.2x4-1BB bispecific will be presented at ESMO Congress in Madrid on 25 October.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Biologics

Pacira grants Molteni exclusive EXPAREL rights across EU and UK

Pacira BioSciences has licensed its liposomal bupivacaine analgesic to Italian firm Molteni Farmaceutici, targeting first commercial sales in Europe by 2027.
Pacira BioSciences has licensed its liposomal bupivacaine analgesic to Italian firm Molteni Farmaceutici, targeting first commercial sales in Europe by 2027.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Biologics

Idorsia daridorexant Phase 2 paediatric data to headline Sleep Europe

Idorsia will present the first clinical data for a dual orexin receptor antagonist in children with insomnia at Sleep Europe 2026 in Maastricht.
Idorsia will present the first clinical data for a dual orexin receptor antagonist in children with insomnia at Sleep Europe 2026 in Maastricht.
The Biotech Times Editorial Team  · 
Medical Devices
Regulatory Science

Manchester-led team maps path for virtual patients in device regulation

A University of Manchester-led consortium has published a framework for using computer-simulated patients to support medical device regulatory decisions.
A University of Manchester-led consortium has published a framework for using computer-simulated patients to support medical device regulatory decisions.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Regulatory Science

Agomab to present STENOVA OLE data at UEG Week 2026

Agomab's ontunisertib Phase 2a extension data in fibrostenosing Crohn's disease will be presented orally at UEG Week as the company readies its Phase
Agomab's ontunisertib Phase 2a extension data in fibrostenosing Crohn's disease will be presented orally at UEG Week as the company readies its Phase
The Biotech Times Editorial Team  · 
Pharmaceuticals
Regulatory Science

Pharvaris HAE pill data published in The Lancet ahead of FDA review

Phase 3 RAPIDe-3 results for oral deucrictibant met all 12 endpoints, with symptom onset relief in 1.28 hours; an FDA decision is due
Phase 3 RAPIDe-3 results for oral deucrictibant met all 12 endpoints, with symptom onset relief in 1.28 hours; an FDA decision is due
The Biotech Times Editorial Team  · 
Biologics
Pharmaceuticals

argenx halts Phase 3 UNITY trial of efgartigimod in Sjögren's disease

An independent data monitoring committee recommended stopping the UNITY study for futility after an interim analysis found it unlikely to meet its primary endpoint.
An independent data monitoring committee recommended stopping the UNITY study for futility after an interim analysis found it unlikely to meet its primary endpoint.
The Biotech Times Editorial Team  · 
Cell & Gene Therapy
Biologics
Medical Devices

GenSight optogenetic therapy safe and restores object detection

A first clinical cohort of ten blind retinitis pigmentosa patients showed meaningful light sensitivity gains with GenSight's gene therapy and goggle system.
A first clinical cohort of ten blind retinitis pigmentosa patients showed meaningful light sensitivity gains with GenSight's gene therapy and goggle system.
The Biotech Times Editorial Team  · 
Biologics
Pharmaceuticals

argenx Phase 2 data back FB102 as first drug for celiac disease

argenx's CD122 inhibitor FB102 met its primary histological endpoint in a 126-patient Phase 2 gluten-challenge trial, with a Phase 3 programme now
argenx's CD122 inhibitor FB102 met its primary histological endpoint in a 126-patient Phase 2 gluten-challenge trial, with a Phase 3 programme now
The Biotech Times Editorial Team  · 
Pharmaceuticals
Biologics

RougeTx launches with $58m Series A to target HHT bleeding disorder

The Leiden spin-out is advancing RTX-001, a once-daily oral pericyte-targeting candidate, toward first-in-human trials in a condition with no
The Leiden spin-out is advancing RTX-001, a once-daily oral pericyte-targeting candidate, toward first-in-human trials in a condition with no
The Biotech Times Editorial Team  · 
Biologics
Pharmaceuticals

Epcoritamab plus R-CHOP cuts DLBCL progression risk by 51% in Phase 3

Genmab and AbbVie say their EPCORE DLBCL-2 trial is the first Phase 3 bispecific study to hit a PFS endpoint in frontline diffuse large
Genmab and AbbVie say their EPCORE DLBCL-2 trial is the first Phase 3 bispecific study to hit a PFS endpoint in frontline diffuse large
The Biotech Times Editorial Team  · 
Cell & Gene Therapy
Genomics

AAVantgarde sees early efficacy signals in dual-AAV eye therapy

AAVantgarde Bio presented Phase 1/2 data showing visual function gains in Usher syndrome and strong preclinical support for its Stargardt programme at EURetina 2026.
AAVantgarde Bio presented Phase 1/2 data showing visual function gains in Usher syndrome and strong preclinical support for its Stargardt programme at EURetina 2026.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Bioprocessing

Samfara acquires Chr. Olesen Synthesis in controlled-substance API deal

London PE firm Samfara has completed its first acquisition, buying Danish cGMP manufacturer Chr. Olesen Synthesis, which specialises in buprenorphine and lisdexamfetamine
London PE firm Samfara has completed its first acquisition, buying Danish cGMP manufacturer Chr. Olesen Synthesis, which specialises in buprenorphine and lisdexamfetamine
The Biotech Times Editorial Team  · 
Subscribe to UK & Europe